Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient
Ημερομηνία
2021Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the PD1 inhibitor nivolumab on humoral immunity by following the levels of antibodies against hepatitis B surface antigen (anti-HBs) in a hemodialysis patient successfully vaccinated against hepatitis B virus 5 years ago and now starting nivolumab for renal cell carcinoma lung metastases. Anti-HBs kinetics after administration of an extra vaccine dose were also evaluated. Nivolumab increased anti-HBs and facilitated a further increase following an additional vaccine dose. The observed time frame indicates that nivolumab boosts humoral immune response by affecting long-lived plasma cells and at least memory B cells. This may protect cancer patients from pathogens encountered in the past or against which vaccination has been performed and provide information for the emerging immune checkpoint inhibitors administration concept against chronic infectious diseases. © 2021 Lippincott Williams and Wilkins. All rights reserved.
Collections
Related items
Showing items related by title, author, creator and subject.
-
The immunopathogenetic role of autoantibodies in canine autoimmune hepatitis: Lessons to learn from human autoimmune hepatitis
Liaskos, C.; Mavropoulos, A.; Orfanidou, T.; Spyrou, V.; Athanasiou, L. V.; Billinis, C. (2012)Autoimmune hepatitis (AIH) is not a disease entity restricted to man, but it can be found in other animals including canines. An increasing number of studies have focused on the immunopathogenesis of human autoimmune ... -
Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: Is there a role in clinical practice?
de Mello R.A., Zhu J.-H., Iavelberg J., Potim A.H., Simonetti D., Júnior J.A.S., Castelo-Branco P., Pozza D.H., Tajima C.C., Tolia M., Antoniou G. (2020)[No abstract available] -
p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B
Bakarozi M., Mavropoulos A., Bogdanos D.P., Dalekos G.N., Rigopoulou E.I. (2020)The mitogen-activated protein kinase p38 (MAPK) is implicated in the induction of immune responses by regulating the differentiation of T lymphocytes and production of cytokines. Our aim was to investigate p38MAPK ...